These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 24378783)

  • 41. Evolving Outsourcing Landscape in Pharma R&D: Different Collaborative Models and Factors To Consider When Choosing a Contract Research Organization.
    DeCorte BL
    J Med Chem; 2020 Oct; 63(20):11362-11367. PubMed ID: 32479727
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Industrial-strength bonds.
    Nature; 2015 Nov; 527(7577):S76-9. PubMed ID: 26560455
    [No Abstract]   [Full Text] [Related]  

  • 43. How academic labs can approach the drug discovery process as a way to synergize with big pharma.
    Loregian A; Palù G
    Trends Microbiol; 2013 Jun; 21(6):261-4. PubMed ID: 23731493
    [TBL] [Abstract][Full Text] [Related]  

  • 44. AI drug discovery booms in China.
    Cyranoski D
    Nat Biotechnol; 2021 Aug; 39(8):900-902. PubMed ID: 34345035
    [No Abstract]   [Full Text] [Related]  

  • 45. Compound Passport Service: supporting corporate collection owners in open innovation.
    Andrews DM; Degorce SL; Drake DJ; Gustafsson M; Higgins KM; Winter JJ
    Drug Discov Today; 2015 Oct; 20(10):1250-5. PubMed ID: 26136162
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Golden opportunities.
    Smaglik P
    Nature; 2005 Jul; 436(7047):144-7. PubMed ID: 16007735
    [No Abstract]   [Full Text] [Related]  

  • 47. Ethical issues at the university-industry interface: a way forward?
    Evans GR; Packham DE
    Sci Eng Ethics; 2003 Jan; 9(1):3-16. PubMed ID: 12645225
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Novartis and University of Pennsylvania announce collaboration.
    Sklan A
    Bioanalysis; 2012 Sep; 4(17):2099. PubMed ID: 23013390
    [No Abstract]   [Full Text] [Related]  

  • 49. How to create innovation by building the translation bridge from basic research into medicinal drugs: an industrial perspective.
    Germann PG; Schuhmacher A; Harrison J; Law R; Haug K; Wong G
    Hum Genomics; 2013 Mar; 7(1):5. PubMed ID: 23496921
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Deal watch: Valuation benefits of structure-enabled drug discovery.
    Borshell N; Papp T; Congreve M
    Nat Rev Drug Discov; 2011 Mar; 10(3):166. PubMed ID: 21358725
    [No Abstract]   [Full Text] [Related]  

  • 51. Re-inventing drug development: A case study of the I-SPY 2 breast cancer clinical trials program.
    Das S; Lo AW
    Contemp Clin Trials; 2017 Nov; 62():168-174. PubMed ID: 28899813
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reinventing the antimicrobial pipeline in response to the global crisis of antimicrobial-resistant infections.
    Singer AC; Kirchhelle C; Roberts AP
    F1000Res; 2019; 8():238. PubMed ID: 30906539
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Drug Discovery Portal: a resource to enhance drug discovery from academia.
    Clark RL; Johnston BF; Mackay SP; Breslin CJ; Robertson MN; Harvey AL
    Drug Discov Today; 2010 Aug; 15(15-16):679-83. PubMed ID: 20547242
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Crowd sourcing in drug discovery.
    Lessl M; Bryans JS; Richards D; Asadullah K
    Nat Rev Drug Discov; 2011 Apr; 10(4):241-2. PubMed ID: 21455221
    [No Abstract]   [Full Text] [Related]  

  • 55. Biopharma CRO industry in China: landscape and opportunities.
    Xia C; Gautam A
    Drug Discov Today; 2015 Jul; 20(7):794-8. PubMed ID: 25701282
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Large drug firms narrow their therapeutic interests.
    Mullard A
    Lancet; 2014 May; 383(9932):1873. PubMed ID: 24892171
    [No Abstract]   [Full Text] [Related]  

  • 57. Industry continues dabbling with open innovation models.
    Sheridan C
    Nat Biotechnol; 2011 Dec; 29(12):1063-5. PubMed ID: 22158347
    [No Abstract]   [Full Text] [Related]  

  • 58. Combating the cons of consolidation.
    Nat Rev Drug Discov; 2009 Mar; 8(3):177. PubMed ID: 19263592
    [No Abstract]   [Full Text] [Related]  

  • 59. Open access chemical and clinical probes to support drug discovery.
    Edwards AM; Bountra C; Kerr DJ; Willson TM
    Nat Chem Biol; 2009 Jul; 5(7):436-40. PubMed ID: 19536100
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vertical disintegration: a strategy for pharmaceutical businesses in 2009?
    Dixon J; Lawton G; Machin P
    Nat Rev Drug Discov; 2009 Jun; 8(6):435. PubMed ID: 19483701
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.